MARKET

ATRS

ATRS

Antares Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.060
-0.440
-9.78%
Closed 17:45 03/02 EST
OPEN
4.540
PREV CLOSE
4.500
HIGH
4.540
LOW
4.000
VOLUME
3.10M
TURNOVER
--
52 WEEK HIGH
5.07
52 WEEK LOW
1.600
MARKET CAP
676.69M
P/E (TTM)
71.60
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Antares Pharma's CEO Bob Apple on Q4 2020 Results -- Earnings Call Transcript >ATRS
Dow Jones · 15h ago
Antares Pharma (ATRS) Q4 Earnings Lag Estimates
Zacks.com · 19h ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 19h ago
8-K: ANTARES PHARMA, INC.
(EDGAR Online via COMTEX) -- false 0001016169 0001016169 2021-03-02 2021-03-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 20h ago
BRIEF-Antares Pharma Reports Fourth Quarter And Full-Year 2020 Results
reuters.com · 20h ago
Antares Pharma Q4 EPS $0.03, Inline, Sales $44.13M Beat $40.75M Estimate
Antares Pharma (NASDAQ:ATRS) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $44.13
Benzinga · 20h ago
Antares Pharma EPS beats by $0.26, beats on revenue; reaffirms guidance
Antares Pharma (ATRS): Q4 GAAP EPS of $0.30 beats by $0.26.Revenue of $44.1M (+16.5% Y/Y) beats by $1.79M.FY2021 guidance: revenue in the range of $175M-200M, which represents a 17% to
Seekingalpha · 20h ago
Antares Pharma Backs FY Rev $175M-$200M >ATRS
Antares Pharma Backs FY Rev $175M-$200M >ATRS
Dow Jones · 20h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRS stock price target is 6.42 with a high estimate of 8.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 245
Institutional Holdings: 82.17M
% Owned: 49.30%
Shares Outstanding: 166.67M
TypeInstitutionsShares
Increased
49
3.24M
New
35
5.94M
Decreased
50
3.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.55%
Healthcare Equipment & Supplies
-0.56%
Key Executives
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.